Insights
Search Results
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
2.18.25
Wilson Sonsini Advises Esperto Medical on Oversubscribed Series A
On February 18, 2025, Esperto Medical™, a healthtech start-up specializing in critical care and remote patient monitoring, announced the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures. Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction.
Client Highlights
9.11.24
Wilson Sonsini Advises SpectraWAVE on $50 Million Series B Financing
On September 11, 2024, SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), announced a $50 million Series B funding round. The round was led by Johnson & Johnson Innovation - JJDC, Inc. and joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital. Wilson Sonsini Goodrich & Rosati advised SpectraWAVE on the transaction.
The funding round will be used to advance commercial expansion and product additions to the company’s 510k-cleared HyperVue™ Imaging System. HyperVue is the first intravascular imaging technology to combine two important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.
The Wilson Sonsini team that advised SpectraWAVE includes Jason Skolnik, Brandon Shaw, Trevor Dorne, and Stephanie Chen.
The funding round will be used to advance commercial expansion and product additions to the company’s 510k-cleared HyperVue™ Imaging System. HyperVue is the first intravascular imaging technology to combine two important imaging technologies, DeepOCT and NIRS, while optimizing for image quality and procedural efficiency in the cath lab, including no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and the most comprehensive AI-driven workflow and image analysis offering.
The Wilson Sonsini team that advised SpectraWAVE includes Jason Skolnik, Brandon Shaw, Trevor Dorne, and Stephanie Chen.
Client Highlights
5.02.24
Firm Advises Novo Holdings on Reunion Neuroscience’s $103 Million Series A
On May 2, 2024, Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, announced the close of a $103 million Series A financing co-led by Novo Holdings and MPM BioImpact, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.
Client Highlights
1.17.24
Wilson Sonsini Advises Cleveland Diagnostics on $75 Million Growth Capital Financing
On January 17, 2024, Cleveland Diagnostics, a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced the closing of over $75 million in growth capital financing led by Novo Holdings with participation from existing investors as well as a credit facility from Symbiotic Capital. Wilson Sonsini Goodrich & Rosati represented Cleveland Diagnostics on the transaction.